SGMT

Sagimet Biosciences Inc. Health Care Pharmaceutical Preparations Russell 3000

$9.92Close $4.55 – $11.1752-week range Nov 12, 2026Next report

Highlights

Strengths

Leading the market RS 90 · stronger than 90% of stocks over 12 months

Cautions

Trend not confirmed 7 of 8 conditions · under the 50-day
Results soon Nov 12, 2026, in 11 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 11, 2026

Off 12-month high 11%

1wk 3.5% price change

1mo 0.4% price change

12-month return 22% market up 11% · its own up 8%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B — price / book

Earnings yield — EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 38% return on equity

Free cash margin — -$45.6M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 6.5% $0.64 a day · 2×ATR $8.64

RS 90 / 99 vs the universe

Trend 7 / 8 under the 50-day

Relative volume 0.8× vs 50-day average

Up/down volume 0.97 50 sessions

Implied move — no option chain · report Nov 12, 2026

Trend template · 7 of 8

Price above the 50-day average: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Aug 11, 2026

Last shock Sep 24, 2026-13% in one session3.2× volumeno filing matched+9% since

Financials

4 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$51.0M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$45.6M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology

	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	—	$2.0M	—	—
Operating income	-$31.1M	-$30.7M	-$54.5M	-$56.9M
Net income	-$30.5M	-$27.9M	-$45.6M	-$51.0M
Net margin	—	-1394%	—	—
Earnings per share	-$165.20	-$2.66	-$1.45	-$1.58
Free cash flow	-$24.5M	-$23.8M	-$42.4M	-$45.6M
Free cash margin	—	-1188%	—	—
Cash	$158,000	$75.1M	$75.8M	$35.0M
Shareholders' equity	-$186.9M	$91.1M	$155.8M	$111.4M
Shares outstanding	185.08k	0	—	—

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 11, 2026	Quarterly ↗	Jun 30, 2026	42d
May 12, 2026	Quarterly ↗	Mar 31, 2026	42d
Mar 11, 2026	Annual ↗	Dec 31, 2025	70d
Nov 13, 2025	Quarterly ↗	Sep 30, 2025	44d
Aug 13, 2025	Quarterly ↗	Jun 30, 2025	44d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Mar 12, 2025	Annual ↗	Dec 31, 2024	71d
Nov 14, 2024	Quarterly ↗	Sep 30, 2024	45d
Aug 14, 2024	Quarterly ↗	Jun 30, 2024	45d
May 15, 2024	Quarterly ↗	Mar 31, 2024	45d
Mar 25, 2024	Annual ↗	Dec 31, 2023	85d
Nov 13, 2023	Quarterly ↗	Sep 30, 2023	44d

Current reports

Filed	Disclosed
Oct 22, 2026	Regulation FD ↗
Oct 1, 2026	Material agreement ↗
Sep 30, 2026	Regulation FD · Other events ↗
Aug 13, 2026	Other events ↗
Aug 11, 2026	Results · Regulation FD ↗
Jul 21, 2026	Regulation FD ↗
Jun 12, 2026	Director or officer change · Shareholder vote ↗
Jun 3, 2026	Director or officer change ↗
May 12, 2026	Results ↗
Apr 28, 2026	Material agreement ↗
Apr 27, 2026	Regulation FD ↗
Apr 27, 2026	Results · Regulation FD · Other events ↗